Neuroblastoma is one of the most commonly diagnosed solid cancers for children, and genetic factors may play a critical role in neuroblastoma development. Previous genome-wide association studies (GWASs) have identified nine genes associated with neuroblastoma susceptibility in Caucasians. To determine whether genetic variations in these genes are also associated with neuroblastoma susceptibility in Southern Chinese children, we genotyped 25 polymorphisms within these genes by the TaqMan method in 256 cases and 531 controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the strength of the associations. We performed a meta-analysis to further evaluate the associations. Furthermore, we calculated the area under the receiver-operating characteristic curves (AUC) to assess which gene/genes may better predict neuroblastoma risk. We confirmed that CASC15 rs6939340 A N G, rs4712653 T N C, rs9295536 C N A, LIN28B rs221634 A N T, and LMO1 rs110419 A N G were associated with significantly altered neuroblastoma susceptibility. We also confirmed that rs6939340 A N G (G versus A: OR = 1.30, 95% CI = 1.13-1.50) and rs110419 G N A (A versus G: OR = 1.37, 95% CI = 1.19-1.58) were associated with increased neuroblastoma risk for all subjects. We also found that the combination of polymorphisms in CASC15, LIN28B, and LMO1 may be used to predict neuroblastoma risk (AUC = 0.63, 95% CI = 0.59-0.67). Overall, we verified five GWAS-identified polymorphisms that were associated with neuroblastoma susceptibility alteration for Southern Chinese population; however, these results need further validation in studies with larger sample sizes.
Introduction
Neuroblastoma is one of the most frequently occurring childhood tumors worldwide, affecting approximately 7.7 children per million in the Chinese population and accounting for approximately 9.8% of solid tumors in children [1] . Ethnic differences may influence the incidence of neuroblastoma. In the United States and most European
countries, neuroblastoma accounts for approximately 7% to 10% of all childhood cancers with a standardized incidence rate of 8 to 14 neuroblastoma cases per million [2, 3] . In the Taiwan area, the incidence is approximately 7.8 children per million, which is quite similar to mainland China [4] . As for other countries, the incidence rate in children is approximately 9.6 per million for Australia [5] , 4.5 per million for India [6] , 9.1 per million for Uruguay, 4.7 per million for Chile, 3.8 per million for Mexico, 5.9 per million for Brazil, and 8.3 per million for Argentina [7] . To date, no environmental factors have been found to lead to the occurrence of neuroblastoma [8, 9] , suggesting that genetic factors may play a crucial role in the occurrence of neuroblastoma [10] [11] [12] [13] .
Because of the increased human genome knowledge and advancements in genotyping technology developed in the past decade, genome-wide association studies (GWASs) of human diseases became possible and have been widely utilized to study diseases such as cancer [14, 15] . In 2008, the first GWAS for neuroblastoma was conducted by Maris et al. [16] , which included 1032 neuroblastoma patients and 2043 controls of European descent and was then confirmed with an additional 720 cases and 2128 controls. They confirmed that three polymorphisms (rs6939340 A N G, rs4712653 T N C, and rs9295536 C N A) within the CASC15 (also known as LINC00340) gene at the 6p22 chromosomal region were significantly associated with neuroblastoma susceptibility. When focusing on a high-risk subset, they found that common variations in the BARD1 gene at 2q35 were associated with high-risk neuroblastoma [17] . They also found that polymorphisms within DUSP12 at 1q23.3, DDX4 and IL31RA at 5q11.2, and HSD17B12 at 11p11.2 were associated with low-risk neuroblastoma [18] . In the fourth GWAS, by enlarging the sample size to 2251 cases and 6097 controls of European descent from four case series, Wang et al. [19] confirmed that four polymorphisms, especially the rs110419 A N G polymorphism within the LMO1 gene at 11p15.4 region, were significantly associated with altered susceptibility to neuroblastoma. In addition, Diskin et al. [20] analyzed data from 2817 neuroblastoma patients and 7473 controls and found that polymorphisms in the LIN28B and HACE1 genes at 6q16 were associated with neuroblastoma susceptibility.
The associations between polymorphisms within these GWAS-identified genes and neuroblastoma susceptibility have been validated in African-Americans [21] , Italians [22] , and Northern [23] and Southern Chinese children [24] [25] [26] [27] [28] [29] . Genetic background may differ among Europeans, African-Americans, and Chinese subjects, even among different regions of China. In the present study, we describe the relationship between genetic variations of the nine GWAS-identified genes and neuroblastoma susceptibility in Southern Chinese children including 256 cases and 531 controls. We also performed a meta-analysis to assess the association of the CASC15 rs6939340 A N G and LMO1 rs110419 G N A polymorphisms with neuroblastoma susceptibility for Southern Chinese children. We also calculated the area under the receiver-operating characteristic curves (AUC) to assess which gene/genes can best predict neuroblastoma susceptibility.
Materials and Methods

Study Subjects
This study consists of 256 neuroblastoma patients and 531 cancer-free controls that were matched by age, gender, and ethnicity as we described previously (Supplemental Table 1 ) [26, 30, 31] . Briefly, histopathologically confirmed neuroblastoma cases were recruited mainly between February 2010 and November 2015 with written, informed consent by their guardians. All the controls were collected in the same period from the Guangzhou Women and Children's Medical Center. This study was approved by the Institutional Review Board of Guangzhou Women and Children's Medical Center. 
Genotyping and Quality Control
We genotyped the 25 polymorphisms within the nine GWAS-identified genes by TaqMan real-time PCR [32, 33] . To monitor quality control, eight negative controls (water) as well as eight replicate samples were included in each 384-well plate. Additionally, approximately 10% of the samples were randomly selected for further quality control, and the results were 100% concordant.
Meta-Analysis
We performed a meta-analysis by collecting data from all available publications on the CASC15 rs6939340 A N G and LMO1 rs110419 G N A polymorphisms. Crude odds ratios (ORs) and 95% confidence intervals (CIs) were used to investigate the strength of the associations under an allele-comparing model. Heterogeneity was measured by a χ 2 -based Q test. Random-effect modeling was used when P het b .1 [34] .
Statistical Analysis
We applied χ 2 tests to compare categorical variables such as demographics and genotype frequencies. We used the goodness-of-fit χ 2 test to assess the Hardy-Weinberg equilibrium for controls by using the observed genotypes for each polymorphism. Associations of the selected polymorphisms and the combined genotypes for the three most significant polymorphisms from each region with neuroblastoma susceptibility were estimated by ORs and 95% CIs were calculated using unconditional logistic regression with adjustment for age and gender. We adopted a nonparametric approach to compare the area under the receiver operating characteristic (ROC) curves (AUC) for the polymorphisms from the three most significant genes and the combined genes [35] . All statistical analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, USA). All the P values were two sided, and P b .05 was considered statistically significant.
Results
Associations between Selected Polymorphisms and Neuroblastoma Susceptibility
As shown in Table 1 , of the 25 selected polymorphisms, we confirmed that five were associated with neuroblastoma susceptibility: CASC15 gene polymorphisms rs6939340 G N A, rs4712653 C N T, and rs9295536 A N C; LIN28B gene polymorphism rs221634 A N T; and LMO1 gene polymorphism rs110419 A N G. No significant associations were observed for other polymorphisms.
Estimates of Neuroblastoma Risk by Genotype
As shown in Table 2 , we chose one of the most significant polymorphisms from each of the three regions (rs6939340, rs221634, and rs110419) to assess the joint impact on neuroblastoma risk. When the rs6939340 AG/AA, rs221634 AA/AT, and rs110419 GG/ AG carriers were used as a reference, we found that risk genotype carriers may have increased neuroblastoma risk, particularly carriers of the rs6939340 GG, rs221634 TT, and rs110419 AA polymorphisms (adjusted OR = 4.11, 95% CI = 1.95-9.66).
Meta-Analysis Results
As shown in Table 3 and Figure 1 , analysis of the rs6939340 G N A polymorphism in 3302 neuroblastoma cases and 8279 controls found that carrying the rs6939340 G allele is associated with increased neuroblastoma risk (G versus A: OR = 1.37, 95% CI = 1.19-1.58, P = 1.97*10 −5 ). Similarly, for the rs110419 A N G polymorphism, a total of 3289 cases and 8303 controls were analyzed, and the combined results indicated that this polymorphism was significantly associated with neuroblastoma susceptibility (A versus G: OR = 1.30, 95% CI = 1.13-1.50, P = 3.15*10 −4 ) (Figure 1 ).
AUC for GWAS-Identified Genes
As shown in Figure 2 , when all the polymorphisms for each gene are compared, the CASC15 gene (AUC = 0.59, 95% CI = 0.55-0.63) is a better predictor of neuroblastoma risk than the LMO1 gene (AUC = 0.56, 95% CI = 0.52-0.60) or LIN28B gene (AUC = 0.54, 95% CI = 0.51-0.58). However, these three genes combined have an AUC of 0.63 (95% CI = 0.59-0.67). When all the polymorphisms from the nine genes were combined, the AUC was further improved to 0.66 (95% CI = 0.61-0.70).
Discussion
In the described hospital-based case-control study with 256 neuroblastoma cases and 531 cancer-free controls from south China, we systematically evaluated the associations between polymorphisms derived from nine GWAS-identified genes and confirmed the role of five polymorphisms in predicting neuroblastoma susceptibility. We also found that risk genotype carriers have a significantly increased neuroblastoma risk, as high as 4.11-fold. By analyzing data from all available publications, we further confirmed that the CASC15 rs6939340 G N A and LMO1 rs110419 A N G polymorphisms were significantly associated with neuroblastoma risk.
In addition to environmental factors, genetic factors may also play a crucial role in the occurrence of neuroblastoma [13] . GWAS is a powerful tool in identifying disease-related loci. It has significantly improved our understanding of the genetic basis of cancer, providing the basis for discovering new options for targeted prevention and therapy [14] . To date, nine susceptibility genes have been discovered [16] [17] [18] [19] [20] , and among them, polymorphisms within the CASC15, LMO1, LIN28B, and HCAE1 genes are significantly associated with neuroblastoma risk, including but not limited to high-risk and low-risk subtypes. The first identified and most prominent polymorphism associated with neuroblastoma was CASC15 rs6939340 G N A (P = 9.33 × 10 −15 ) at 6p22 region. Two additional CASC15 gene polymorphisms (rs4712653 with P = 5.50*10 −13 and rs9295536 with P = 1.24*10 −11 ) were also associated with neuroblastoma susceptibility [16] . Following this discovery, using data from 1627 cases and 3254 controls in the discovery stage and 624 cases and 2843 controls in the replication stage, Wang et al. [19] discovered four LMO1 gene polymorphisms (rs110419 A N G, rs4758051 G N A, rs10840002 A N G, and rs204938 A N G) that were associated with neuroblastoma susceptibility. Among these polymorphisms, the rs110419 A N G was the most noteworthy one. In 2012, Diskin et al. [20] found that five polymorphisms in the HACE1 gene and one polymorphism in the LIN28B gene were associated with neuroblastoma susceptibility including a total of 10,290 subjects. It is also worth noting that BARD1 gene polymorphisms have been reported to be associated with high-risk neuroblastoma [17] .
In their replication study consisting of African-Americans with 391 cases and 2500 controls, Latorre et al. [21] analyzed a total of 12 polymorphisms from the CASC15, BARD1, and LMO1 genes and confirmed that all of the five polymorphisms in the BARD1 gene were associated with neuroblastoma risk. However, they failed to confirm the effects of the CASC15 and LMO1 genes. In a replicated study in an Italian population with 370 cases and 809 controls, Capasso et al. [22] investigated 16 polymorphisms from the nine GWAS-identified genes and successfully confirmed the association of the CASC15, BARD1, LMO1, and HSD17B12 genes. As for Northern Chinese subjects, Lu et al. [23] analyzed a total of 244 cases and 305 controls and found that polymorphisms in the CASC15, LMO1, and HSD17B12 genes were associated with neuroblastoma susceptibility. In this study of Southern Chinese children, we confirmed that five polymorphisms within the nine GWAS-identified genes were associated with neuroblastoma susceptibility. Our meta-analysis also confirmed that the CASC15 rs6939340 G N A and LMO1 rs110419 A N G polymorphisms were significantly associated with increased neuroblastoma risk. Our failure to confirm an association with the additional polymorphisms may be due to the weak effect of SNPs, limited sample size, and ethnicity differences.
Several limitations should be mentioned. First, the sample size (256 neuroblastoma cases) is relatively small despite us including all the samples available. More samples from other regions of China should be investigated and combined in future multicenter studies. Second, we only included 25 polymorphisms in these nine genes and nearly none of them was potential functional according to SNPinfo (https://snpinfo.niehs.nih.gov/snpinfo/snpfunc.html); inclusion of more polymorphisms, in particular, the potential functional ones [33] as well as low-frequency variants [36] , needs to be considered. Third, we only investigated nine genes by previous GWAS; the latest ones such as MLF1 and CPZ [37] were not included in the current study. Fourth, relatively limited information was collected due to the nature of retrospective investigations. Other factors such as paternal exposures, living environment, and dietary intake were not available.
In summary, we provide an overview of the genetic variations within the GWAS-identified genes associated with neuroblastoma susceptibility in Southern Chinese children. Further investigations with larger samples and different ethnicities are needed to validate and confirm the effect of GWAS-identified genes for neuroblastoma susceptibility.
Supplementary data to this article can be found online at https:// doi.org/10.1016/j.tranon.2017.09.008. Figure 2 . ROC analysis for single and combined genes identified from GWAS for neuroblastoma. The areas under the ROC curves (AUCs) were calculated to measure the predictive power of risk-assessment models based on polymorphisms within gene/genes.
